MARKET

PACB

PACB

Pacific Biosc
NASDAQ
8.59
+0.21
+2.51%
After Hours: 8.59 0 0.00% 18:10 12/08 EST
OPEN
8.25
PREV CLOSE
8.38
HIGH
8.67
LOW
8.18
VOLUME
2.91M
TURNOVER
0
52 WEEK HIGH
14.55
52 WEEK LOW
5.74
MARKET CAP
2.30B
P/E (TTM)
-6.7204
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PACB last week (1127-1201)?
Weekly Report · 6d ago
Weekly Report: what happened at PACB last week (1120-1124)?
Weekly Report · 11/27 09:30
Analyzing ARKG's Trading Activity In Q3
Ark genomic revolution etf focuses on genomic innovation in sectors such as healthcare, information technology, and energy. The fund's buying and selling activity gives us clues about the fund's trading activity in the third quarter of 2013. Arkg is a passively managed exchange-traded fund.
Seeking Alpha · 11/23 04:31
Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now
Pacific biosciences of california is a biotechnology company specializing in genetic sequencing for healthcare, agriculture, and environmental science. Pacb's acquisition of apton biosystems aims to integrate short-read technologies and capture a larger share of the sequencing market. Illumina attempted to buy pacb in 2018, but the deal was blocked. Pacbio's revio and onso lead looks priced in for now. Pacb's aggressive valuation suggests limited upside or downside, and a "hold" rating.
Seeking Alpha · 11/22 03:50
Reassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market Dynamics
Pacific biosciences of california reported a 72% yoy revenue growth in q3 2023, driven by the successful launch of their revio platform. Revio's potential to convert existing customers from sequel ii/iie systems highlights the platform's potential. Pacbio reported a revenue surge of 72% year-over-year to $55.7 million.
Seeking Alpha · 11/21 03:03
Weekly Report: what happened at PACB last week (1113-1117)?
Weekly Report · 11/20 09:30
UBS Upgrades Pacific Biosciences of California (PACB)
NASDAQ · 11/18 11:07
Pacific Biosciences of California rise after UBS upgrades on strong 'Revio' demand
Pacific biosciences of california rises after ubs upgrades on strong 'revio' demand. Ubs sees 45% revenue growth in 2024 revio placements. Revio system is a product with long-read sequencing at scale. The sequencing systems company rose 3.16% pre-market.
Seeking Alpha · 11/17 14:25
More
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The Company has developed Single Molecule, Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid (DNA) molecules. The Company’s products include Revio, Sequel, Sequel II and Sequel IIe instruments that conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Once sequencing is started, the real-time data is delivered to the system’s primary analysis pipeline, which outputs base identity and quality values.

Webull offers Pacific Biosciences of California Inc stock information, including NASDAQ: PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PACB stock methods without spending real money on the virtual paper trading platform.